Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.9238 -0.0536 (-5.48%)
Delayed Quote Updated: 3:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming Scientific Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming October Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming September Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming August Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming July Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming June Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
Includes Full Exercise of $15.0 million Over-Allotment Option 
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Provides Business Update with First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at April 2026 Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
From Ocugen
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.